An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...
SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) ...
A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to cancer cells and not normal cells, potentially allowing clinicians to ...
Pretreatment with EZH2 inhibitor (top right) leads to higher recruitment of CAR-T cells (red) into the lymph node tumor compared with control (top left). Pretreatment with EZH2 inhibitor (bottom right ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback